162
Participants
Start Date
January 31, 2009
Primary Completion Date
October 31, 2011
Study Completion Date
March 31, 2012
Cicletanine
Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
Cicletanine Placebo
Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
ULB Hôpital Erasme, Brussels
University Klinik Wien, Vienna
St Vincent's Hospital, Darlinghurst
Royal Perth Hospital, Perth
University Klinik Graz, Graz
H Clinic i Provincial, Barcelona
Beth Israel Medical Center, New York
Cornell University, New York
Mount Sinai Medical Center, New York
New York Presbyterian Hospital, New York
University of Rochester, Rochester
Allegheny General Hospital, Pittsburgh
University of Pittsburgh Medical Center, Pittsburgh
University of Pennsylvania, Philadelphia
University of Maryland, Baltimore
University Of Virginia, Charlottesville
University of North Carolina at Chapel Hill, Chapel Hill
HU 12 de Octubre, Madrid
Emory University, Atlanta
Medical College of Georgia, Augusta
University of Florida, Gainesville
Cleveland Clinic, Fort Lauderdale
Universitaetsklinikum Giessen und Marburg, Giessen
University of South Alabama, Mobile
Case Medical Center, Cleveland
The Lindner Clinical Trial Center, Cincinnati
Rabin Medical Center, Petah Tikva
University of Iowa, Iowa City
Chaim Sheba Medical Center, Ramat Gan
Mayo Clinic, Rochester
University of Chicago Hospital, Chicago
Washington University School of Medicine, St Louis
Unidad de Investigación Clínica en Medicina S.C., Monterrey
Louisiana State University, New Orleans
University of Texas Southwestern Medical Center at Dallas, Dallas
Baylor College of Medicine, Houston
University of Colorado Denver, Aurora
Ludwig-Maximilians-Universitaet, Munich
Intermountain Medical Center, Murray
Arizona Pulmonary Specialists, Phoenix
VA Greater LA Healthcare System, Los Angeles
UCLA Medical Center, Torrance
University of California San Diego Medical Center, San Diego
Harish H. K. Murthy, MD, San Jose
University of Connecticut Health Center, Farmington
Tufts-New England Medical Center, Boston
Massachusetts General Hospital, Boston
Children's Hospital Boston, Boston
Boston University School of Medicine, Boston
Davis Heart and Lung Research Institute, Columbus
Rhode Island Hospital, Providence
Peter Lougheed Centre, Calgary
London Health Sciences Centre, London
Jewish General Hospital, Montreal
Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City
Royal Free Hospital, London
Lead Sponsor
Gilead Sciences
INDUSTRY